Advertisement

Other Cancers: Small-Bowel Cancers, Cholangiocarcinoma, Urinary Tract, and Anal Cancer Risk and Screening in Inflammatory Bowel Disease

  • Fernanda Dal Bello
  • Alan C. MossEmail author
Chapter

Abstract

Patients with inflammatory bowel disease (IBD) are at increased risk for developing extra-colonic cancer at both sites of inflammation (small intestine, biliary tree) and in noninvolved organs (skin, urinary tract). This is due to the neoplastic effects of chronic inflammation or as a risk of chronic immunosuppressive therapies. These cancers are mostly rare, and early detection can be a challenge; therefore, universal screening is of uncertain value.

Keywords

Inflammatory bowel disease Surveillance Cholangiocarcinoma Skin cancer Cervical cancer 

References

  1. 1.
    Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011;140(6):1807–16.CrossRefGoogle Scholar
  2. 2.
    O’Donovan P, Perrett CM, Zhang X, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005;309:1871–4.CrossRefGoogle Scholar
  3. 3.
    DiSario JA, Burt RW, Vargas H, et al. Small bowel cancer: epidemiological and clinical characteristics from a population-based registry. Am J Gastroenterol. 1994;89:699–701.PubMedGoogle Scholar
  4. 4.
    Chow JS, Chen CC, Ahsan H, et al. A population-based study of the incidence of malignant small-bowel tumors: SEER 1973–1990. Int J Epidemiol. 1996;25:722–8.CrossRefGoogle Scholar
  5. 5.
    Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517.CrossRefGoogle Scholar
  6. 6.
    Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982–1018.CrossRefGoogle Scholar
  7. 7.
    ECCO Guideline. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015.Google Scholar
  8. 8.
    Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther. 2004.Google Scholar
  9. 9.
    Elriz K, Carrat F, Carbonnel F, et al. Incidence, presentation, and prognosis of small bowel adenocarcinoma in patients with small bowel Crohn’s disease: a prospective observational study. Inflamm Bowel Dis. 2013.Google Scholar
  10. 10.
    Shaukat A, Virnig DJ, Howard D, Sitaraman SV, Liff JM, Lederle FA. Crohn’s disease and small bowel adenocarcinoma: a population-based case-control study. Cancer Epidemiol Biomark Prev. 2011;20(6):1120–3.CrossRefGoogle Scholar
  11. 11.
    Cahill C, Gordon PH, Petrucci A, Boutros M. Small bowel adenocarcinoma and Crohn’s disease: any further ahead than 50 years ago?. World J Gastroenterol. 2014.Google Scholar
  12. 12.
    Lashner BA. Risk factors for small bowel cancer in Crohn’s disease. Dig Dis Sci. 1992;37(8):1179–84.CrossRefGoogle Scholar
  13. 13.
    Solem CA, Harmsen WS et al. Small intestinal adenocarcinoma in Crohn’s disease: a case-control study. Inflamm Bowel Dis. 2004.Google Scholar
  14. 14.
    Piton G, Cosnes J, Monnet E, et al. Risk factors associated with small bowel adenocarcinoma in Crohn’s disease: a case-control study. Am J Gastroenterol. 2008.Google Scholar
  15. 15.
    Dossett LA, White LM, Welch DC, et al. Small bowel adenocarcinoma complicating Crohn’s disease: case series and review of the literature. Am Surg. 2007;73(11):1181–7.PubMedGoogle Scholar
  16. 16.
    Tirkes AT, Duerinckx AJ. Adenocarcinoma of the ileum in Crohn disease. Abdom Imaging. 2005.Google Scholar
  17. 17.
    Welzel TM, McGlynn KA, Hsing AW, et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006.Google Scholar
  18. 18.
    Khaderi SA, Sussman NL. Screening for malignancy in primary sclerosing cholangitis (PSC). Curr Gastroenterol Rep. 2015;17(4):17.CrossRefGoogle Scholar
  19. 19.
    Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99(3):523–6.CrossRefGoogle Scholar
  20. 20.
    Welzel TM, Mellemkjaer L, Gloria G, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer. 2007.Google Scholar
  21. 21.
    Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012.Google Scholar
  22. 22.
    Rudolph G, Gotthardt D, Kloeters-Plachky P, Rost D, et al. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol. 2010;53(2):313–7.CrossRefGoogle Scholar
  23. 23.
    Singal AK, Stanca CM, Clark V, Dixon L, et al. Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature. Hepatol Int. 2011;5(3):808–13.CrossRefGoogle Scholar
  24. 24.
    Chapman RW, Fevery J, Kalloo A, et al. AASLD practice guidelines: diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010.Google Scholar
  25. 25.
    Beuers U, Boberg KM, Chapman RW, et al. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009.Google Scholar
  26. 26.
    Lindor KD, Kowdley KV, Harrison E. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol. 2015;110:646–59.CrossRefGoogle Scholar
  27. 27.
    Rizvi S, Eaton JE, Gores GJ. Primary sclerosing cholangitis as a premalignant biliary tract disease: surveillance and management. Clin Gastroenterol Hepatol. 2015.Google Scholar
  28. 28.
    Levy C, Lymp J, Angulo P, et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci. 2005;50(9):1734–40.CrossRefGoogle Scholar
  29. 29.
    Sinakos E, Saenger AK, Keach J, Kim WR, Lindor KD. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol. 2011.Google Scholar
  30. 30.
    Marrero JA, Ahn J, Rajender RK. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol. 2014.Google Scholar
  31. 31.
    Pedersen N, Duricova D, Elkjaer M, et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010.Google Scholar
  32. 32.
    Khan N, Vallarino C, Lissoos T, Darr U, Luo M. Risk of malignancy in a nationwide cohort of elderly inflammatory bowel disease patientes. Drugs Aging. 2017.Google Scholar
  33. 33.
    Derikx LA, Nissen LH, Drenth JP, et al. Better survival of renal cell carcinoma in patients with inflammatory bowel disease. Oncotarget. 2015;6(35):38336–47.CrossRefGoogle Scholar
  34. 34.
    Bourrier A, Carrat F, Colombel JF, et al. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Aliment Pharmacol Ther. 2016.Google Scholar
  35. 35.
    Wisniewski A, Flejou JF, Siproudhis L, et al. Anal neoplasia in inflammatory bowel disease: classification proposal, epidemiology, carcinogenesis, and risk management perspectives. J Crohns Colitis. 2017.Google Scholar
  36. 36.
    Beaugerie L, Carrat F, Nahon S, et al. High risk of anal and rectal cancer in patients with anal and/or perianal Crohn’s disease. Clin Gastroenterol Hepatol. 2018.Google Scholar
  37. 37.
    Slesser AA, Bhangu A, Bower M, Goldin R, Tekkis PP. A systematic review of anal squamous cell carcinoma in inflammatory bowel disease. Surg Oncol. 2013.Google Scholar
  38. 38.
    Cranston RD, Regueiro M, Hashash J, et al. A pilot study of the prevalence of anal human papillomavirus and dysplasia in a cohort of patients with IBD. Dis Colon Rectum. 2017.Google Scholar
  39. 39.
    Shah SB, Pickham D, Araya H, et al. Prevalence of anal dysplasia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2015;13:1955–61.CrossRefGoogle Scholar
  40. 40.
    Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunist infections in inflammatory bowel disease. J Crohns Colitis. 2014.Google Scholar
  41. 41.
    Devon KM, Brown CJ, Burnstein M, et al. Cancer of the anus complicating perianal Crohn’s disease. Dis Colon Rectum. 2009;52:211–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Gastroenterology, Center for Inflammatory Bowel DiseaseBeth Israel Deaconess Medical CenterBostonUSA

Personalised recommendations